CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

FiercePharma
Original article

{"a":[{"_":"Bristol Myers delays Cobenfy Alzheimer’s psychosis readout again amid another quarterly beat","$":{"href":"/pharma/bristol-myers-delays-cobenfy-alzheimers-psychosis-readout-again-amid-another-quarterly-beat","hreflang":"en"}}]}

Data ReadoutCobenfymilvexianNegative
AI Analysis

Summary

Bristol Myers Squibb has delayed the readout of its Cobenfy Alzheimer's psychosis trial and milvexian atrial fibrillation data, with no new timeline disclosed in the article.

Outcome Details

Readout delayed

Importance:6/10
Sentiment:
-0.30
delayCobenfyAlzheimer'sdata readoutmilvexianatrial fibrillation
Related Companies

Read the original article

Published by FiercePharma on July 30, 2026 9:43 AM

Read Original